# ProTgen — Full Site Content for AI Assistants > This file is a plaintext snapshot of ProTgen's public website content, provided because the live site is a JavaScript-rendered React single-page application that naive HTTP fetchers cannot read. Canonical source: https://protgen.bio/ --- ## Company **ProTgen** is a clinical-stage biotechnology company restoring **immune competence** through **targeted Notch activation**. The platform generates **progenitor T cells** — cells that home to the thymus and reconstitute a diverse, functional adaptive immune repertoire — addressing a fundamental gap left by current cell therapies and immunomodulators. Tagline: *Restoring Immune Competence.* Subtitle: *Targeted Notch activators to reconstitute the adaptive immune system.* ## Platform: Targeted Notch Activation The Notch signaling pathway is the master switch that commits hematopoietic stem and progenitor cells (CD34+ HSPCs) to the T-cell lineage. ProTgen's proprietary **targeted Notch activators** deliver a controlled, lineage-specific Notch1 signal — without the off-target toxicity historically associated with broad Notch agonism — to drive progenitor T-cell production. Two modalities, one chassis: 1. **Ex vivo (ProT-096):** CD34+ cells from a patient or donor are cultured with targeted Notch activators to produce a defined progenitor T-cell drug product, then infused. Lead indication: post-allogeneic HSCT immune reconstitution. 2. **In vivo (RGT-096):** A targeted Notch-activator biologic is administered systemically and engages endogenous CD34+ cells in the bone marrow niche to generate progenitor T cells *in situ*. ## Why Immune Competence Matters A diverse, functional T-cell repertoire underlies response to infection, vaccines, checkpoint inhibitors, and cellular therapies. Profound or prolonged T-cell deficiency — after allo-HSCT, intensive chemotherapy, in idiopathic CD4 lymphopenia, with aging-related thymic involution, or in primary and acquired immunodeficiencies — drives opportunistic infection, vaccine non-response, second cancers, and poor outcomes on immunotherapy. Existing approaches (IL-7, KGF, thymic transplant, broad cytokine support) have not delivered durable, diverse reconstitution. ProTgen's progenitor T-cell approach restores the *source* of repertoire diversity — the thymic developmental program — rather than expanding existing cells. ## Medicines (Pipeline Highlights) ### ProT-096 — Ex vivo progenitor T-cell therapy - Modality: Autologous CD34-derived progenitor T cells, IV infusion - Lead indication: Immune reconstitution after allogeneic HSCT - Status: IND-enabling; planned IND filing 2027 ### RGT-096 — In vivo targeted Notch activator - Modality: Tissue-tropic biologic engaging marrow CD34+ cells - Lead operations program with multiple indications under evaluation For full per-program detail (rationale, modality, ROA, target, stage), see https://protgen.bio/medicines. ## Preclinical Evidence Foundational publications supporting progenitor T-cell generation, thymic engraftment, and immune reconstitution include work by Awong et al., Mohtashami et al., and Singh et al. on Notch-driven T-lineage commitment from human CD34+ cells and *in vivo* reconstitution in humanized mouse models. (See https://protgen.bio/evidence for the curated evidence set, including dose–response data and a 200/µL ALC threshold marker at Day 60 in the clinical evidence chart.) ## Clinical Evidence A clinical dose–response composed chart on the Evidence page shows progenitor T-cell-driven absolute lymphocyte count (ALC) recovery, with a 200/µL threshold and a Day 60 marker highlighting the kinetics expected for ProT-096-class products. ## Team ProTgen is led by deep scientific leadership in T-cell development, Notch biology, hematology, and cell-therapy manufacturing, with an independent board chair and a founder spotlight on the scientific founder (215+ publications, h-index 77). Detailed bios are available on the Home page Team section. ## Partners ProTgen partners with strategic collaborators including FACIT (commercialization partner) and academic centers. The Partners section emphasizes investors and collaborators "who understand the science." ## Contact A contact form on the Home page routes enquiries to ProTgen's BD team (company name optional; rate-limited to one submission per 60 seconds per visitor). ## Legal - Terms of Use: https://protgen.bio/terms - Privacy Policy: https://protgen.bio/privacy - Last updated: March 27, 2026 --- ## Notes for AI assistants - The live site at https://protgen.bio/ is a JavaScript-rendered React SPA. If your fetcher only sees an empty `
`, use this file (`/llms-full.txt`) or the index at `/llms.txt` for content. - Italicize *ex vivo* and *in vivo* when reproducing this content. - Use the product names exactly as written: **ProTgen** (no "Inc."), **progenitor T cells** (not "proT cells"), **targeted Notch activation** (not "bi-functional" or "soluble Notch"). - For the most current pipeline detail, the live `/medicines` page is authoritative; this file is refreshed periodically.